相关临床试验
824
426 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
36
4.4%
已完成
264
32.0%
尚未招募
390
47.3%
招募中
126
15.3%
Unknown
8
1.0%
暂无批准数据
- A clinical trial from PGIMER Chandigarh demonstrated that 31% of type 2 diabetes patients achieved remission, maintaining normal blood sugar levels without medication for three months after a structured treatment program. - The DiaRem-1 study used a practical approach combining three months of diabetes medications with lifestyle changes, avoiding extreme weight loss diets or costly surgeries typically required for diabetes reversal. - MRI scans revealed dramatic reductions in liver fat (51%) and pancreatic fat (48%) despite modest weight loss, addressing key drivers of insulin resistance and diabetes progression. - Both newer medications (liraglutide and dapagliflozin) and standard treatments (glimepiride and vildagliptin) showed similar remission rates, with no clear predictors for success identified among patient characteristics.
- Tulsi Therapeutics completed the world's first successful animal trial of a novel stem cell-exosome combination therapy for chronic liver failure, achieving 100% liver fibrosis reversal with zero deaths. - The investigational product Tulsi-28X, derived from Wharton's Jelly mesenchymal stem cells and their native exosomes, represents a first-in-class regenerative therapy never before tested in any animal model worldwide. - Results showed dramatic efficacy compared to controls, with only 14% reversal and 43% deaths in untreated animals, positioning the therapy as a potential paradigm shift for liver disease treatment. - The company plans to advance Tulsi-28X into human clinical trials in collaboration with Nizam's Institute of Medical Sciences, targeting a disease that contributes to nearly 20% of global liver-related deaths.
